Skip to content

Total debt at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.36M-2.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$2.73M+27.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Amgen logo
AmgenAMGN
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $2.94M.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's total debt?
Vor Biopharma (VOR) reported total debt of $2.94M in Q1 2026.
How has Vor Biopharma's total debt changed year-over-year?
Vor Biopharma's total debt decreased by 90.5% year-over-year, from $30.78M to $2.94M.
What is the long-term trend for Vor Biopharma's total debt?
Over 5 years (2020 to 2025), Vor Biopharma's total debt has grown at a -30.3% compound annual growth rate (CAGR), from $18.29M to $3M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.